CN114340683A - 用于转基因表达的方法和组合物 - Google Patents

用于转基因表达的方法和组合物 Download PDF

Info

Publication number
CN114340683A
CN114340683A CN202080043579.3A CN202080043579A CN114340683A CN 114340683 A CN114340683 A CN 114340683A CN 202080043579 A CN202080043579 A CN 202080043579A CN 114340683 A CN114340683 A CN 114340683A
Authority
CN
China
Prior art keywords
cell
raav
transgene
polynucleotide
aav
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202080043579.3A
Other languages
English (en)
Chinese (zh)
Inventor
约翰·F·恩格尔哈特
颜子颖
唐应华
埃里克·阮
林深
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Spirovan Science
University of Iowa Research Foundation UIRF
Original Assignee
Spirovan Science
University of Iowa Research Foundation UIRF
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Spirovan Science, University of Iowa Research Foundation UIRF filed Critical Spirovan Science
Publication of CN114340683A publication Critical patent/CN114340683A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
CN202080043579.3A 2019-04-15 2020-04-15 用于转基因表达的方法和组合物 Pending CN114340683A (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201962833979P 2019-04-15 2019-04-15
US62/833,979 2019-04-15
US201962926317P 2019-10-25 2019-10-25
US62/926,317 2019-10-25
US202062967219P 2020-01-29 2020-01-29
US62/967,219 2020-01-29
PCT/US2020/028269 WO2020214672A1 (en) 2019-04-15 2020-04-15 Methods and compositions for transgene expression

Publications (1)

Publication Number Publication Date
CN114340683A true CN114340683A (zh) 2022-04-12

Family

ID=70779846

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080043579.3A Pending CN114340683A (zh) 2019-04-15 2020-04-15 用于转基因表达的方法和组合物

Country Status (13)

Country Link
US (1) US20220195461A1 (https=)
EP (1) EP3955970A1 (https=)
JP (2) JP2022529470A (https=)
KR (1) KR20220047538A (https=)
CN (1) CN114340683A (https=)
AU (1) AU2020257182A1 (https=)
BR (1) BR112021020706A2 (https=)
CA (1) CA3137078A1 (https=)
IL (1) IL287262A (https=)
MX (1) MX2021012682A (https=)
PH (1) PH12021552609A1 (https=)
SG (1) SG11202111353QA (https=)
WO (1) WO2020214672A1 (https=)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114641318A (zh) * 2019-04-15 2022-06-17 衣阿华大学研究基金会 用于治疗囊性纤维化的组合物和方法
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11999965B2 (en) 2017-01-13 2024-06-04 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1

Citations (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090145A2 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
WO2011097456A2 (en) * 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
US20150259395A1 (en) * 2014-03-17 2015-09-17 Avalanche Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
CN105142676A (zh) * 2013-03-14 2015-12-09 夏尔人类遗传性治疗公司 Cftr mrna组合物以及相关方法和用途
CN105431170A (zh) * 2013-04-08 2016-03-23 爱荷华大学研究基金会 嵌合腺相关病毒/博卡病毒细小病毒载体
CN106928336A (zh) * 2017-01-20 2017-07-07 首都医科大学附属北京儿童医院 囊性纤维化患者的cftr基因突变形式及其应用
WO2017139381A1 (en) * 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en) * 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US20180127471A1 (en) * 2016-10-19 2018-05-10 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
WO2018170310A1 (en) * 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
CN110650733A (zh) * 2017-02-28 2020-01-03 阿德夫拉姆生物技术股份有限公司 经过修饰的aav衣壳和其用途
CN114641318A (zh) * 2019-04-15 2022-06-17 衣阿华大学研究基金会 用于治疗囊性纤维化的组合物和方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5478745A (en) 1992-12-04 1995-12-26 University Of Pittsburgh Recombinant viral vector system
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
PT733103E (pt) 1993-11-09 2004-07-30 Targeted Genetics Corp Criacao de elevados titulos de vectores de aav recombinantes
AU707866B2 (en) 1994-12-06 1999-07-22 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant AAV vectors
US5656785A (en) 1995-08-07 1997-08-12 The Charles Stark Draper Laboratory, Inc. Micromechanical contact load force sensor for sensing magnitude and distribution of loads and tool employing micromechanical contact load force sensor
AU5445998A (en) 1996-11-19 1998-06-10 Surgx Corporation A transient voltage protection device and method of making same
AU741605B2 (en) 1996-12-18 2001-12-06 Targeted Genetics Corporation AAV split-packaging genes and cell lines comprising such genes for use in the production of recombinant AAV vectors
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof

Patent Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004090145A2 (en) * 2003-03-31 2004-10-21 University Of Iowa Research Foundation Compounds and methods to enhance raav transduction
WO2011097456A2 (en) * 2010-02-05 2011-08-11 The University Of North Carolina At Chapel Hill Compositions and methods for enhanced parvovirus transduction
CN105142676A (zh) * 2013-03-14 2015-12-09 夏尔人类遗传性治疗公司 Cftr mrna组合物以及相关方法和用途
CN105431170A (zh) * 2013-04-08 2016-03-23 爱荷华大学研究基金会 嵌合腺相关病毒/博卡病毒细小病毒载体
US20150259395A1 (en) * 2014-03-17 2015-09-17 Avalanche Biotechnologies, Inc. Compositions and methods for enhanced gene expression in cone cells
CN106414474A (zh) * 2014-03-17 2017-02-15 阿德夫拉姆生物技术股份有限公司 用于视锥细胞中增强的基因表达的组合物和方法
WO2017139381A1 (en) * 2016-02-08 2017-08-17 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
WO2017155973A1 (en) * 2016-03-07 2017-09-14 University Of Iowa Research Foundation Aav-mediated expression using a synthetic promoter and enhancer
US20180127471A1 (en) * 2016-10-19 2018-05-10 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
CN106928336A (zh) * 2017-01-20 2017-07-07 首都医科大学附属北京儿童医院 囊性纤维化患者的cftr基因突变形式及其应用
CN110650733A (zh) * 2017-02-28 2020-01-03 阿德夫拉姆生物技术股份有限公司 经过修饰的aav衣壳和其用途
US20210130413A1 (en) * 2017-02-28 2021-05-06 Adverum Biotechnologies, Inc. Modified aav capsids and uses thereof
WO2018170310A1 (en) * 2017-03-15 2018-09-20 The University Of North Carolina At Chapel Hill Polyploid adeno-associated virus vectors and methods of making and using the same
CN114641318A (zh) * 2019-04-15 2022-06-17 衣阿华大学研究基金会 用于治疗囊性纤维化的组合物和方法

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
ASHLEY L. COONEY等: "Cystic Fibrosis Gene Therapy: Looking Back, Looking Forward", GENES, vol. 9, no. 11, 7 November 2018 (2018-11-07), pages 8 - 23 *
BRADLEY A. HAMILT ON等: "Polarized AAVR expression determines infectivity by AAV gene therapy vectors", GENE THERAPY, vol. 26, 8 April 2019 (2019-04-08), pages 240 - 249, XP036815850, DOI: 10.1038/s41434-019-0078-3 *
KATHERINE J. D. A. EXCOFFON等: "Directed evolution of adeno-associated virus to an infectious respiratory virus", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 106, no. 10, 10 March 2009 (2009-03-10), pages 3865 - 3870, XP093064067, DOI: 10.1073/pnas.0813365106 *
LINS等: "Delivery of a novel AAV, AV.Tl65-CFTR, to human bronchial epithelial cells from patients with cystic fibrosis augments functional recovery of chloride conductance", PEDIATRIC PULMONOLOGY, vol. 54, no. 2, 1 October 2019 (2019-10-01), pages 218, XP009521879, DOI: 10.1002/ppul.22495 *
卢超;王启钊;许瑞安;: "重组腺相关病毒载体的整合性研究进展", 生命科学, no. 05, 15 May 2010 (2010-05-15), pages 459 - 465 *
宫晓丽;王乐;王玮;付夏;张婷;王晓民;: "阿霉素在小鼠离体培养脑片中增强Ⅱ型腺相关病毒的转导", 首都医科大学学报, no. 06, 14 December 2015 (2015-12-14), pages 902 - 907 *
张凤兰;文朝阳;丁卫;: "腺相关病毒基因治疗载体的改良与应用", 首都医科大学学报, no. 04, 21 August 2009 (2009-08-21), pages 565 - 573 *
朱甫祥;刘泽隆;缪静;屈慧鸽;迟晓艳;: "基于蛋白质剪接的BHK细胞Ser~(660)前断裂的CFTR基因转移", 中国生物化学与分子生物学报, no. 05, 20 May 2010 (2010-05-20), pages 429 - 435 *
殷子斐;王丽娜;王园;凌晨;: "提高重组型腺相关病毒转导效率的研究现状", 生物技术通报, no. 09, 15 September 2015 (2015-09-15), pages 49 - 59 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11702672B2 (en) 2016-02-08 2023-07-18 University Of Iowa Research Foundation Methods to produce chimeric adeno-associated virus/bocavirus parvovirus
US11684679B2 (en) 2016-03-07 2023-06-27 University Of Iowa Research Foundation AAV-mediated expression using a synthetic promoter and enhancer
US12173305B2 (en) 2016-05-26 2024-12-24 University Of Iowa Research Foundation cis and trans requirements for terminal resolution of human bocavirus 1
US11999965B2 (en) 2017-01-13 2024-06-04 University Of Iowa Research Foundation Bocaparvovirus small noncoding RNA and uses thereof
CN114641318A (zh) * 2019-04-15 2022-06-17 衣阿华大学研究基金会 用于治疗囊性纤维化的组合物和方法

Also Published As

Publication number Publication date
MX2021012682A (es) 2022-03-25
KR20220047538A (ko) 2022-04-18
IL287262A (en) 2021-12-01
AU2020257182A1 (en) 2021-12-09
PH12021552609A1 (en) 2022-06-27
BR112021020706A2 (pt) 2022-03-15
JP2023126658A (ja) 2023-09-07
JP2022529470A (ja) 2022-06-22
SG11202111353QA (en) 2021-11-29
WO2020214672A1 (en) 2020-10-22
CA3137078A1 (en) 2020-10-22
US20220195461A1 (en) 2022-06-23
EP3955970A1 (en) 2022-02-23

Similar Documents

Publication Publication Date Title
JP7731801B2 (ja) 嚢胞性線維症の治療のための組換えアデノ随伴ウイルス
CN114340683A (zh) 用于转基因表达的方法和组合物
CN105431170B (zh) 嵌合腺相关病毒/博卡病毒细小病毒载体
US8137962B2 (en) Compositions for treating cystic fibrosis
CN116096431A (zh) 肽修饰的aav衣壳
EP2660325A2 (en) AAV vectors and corresponding nucleotide sequences and methods
JP2016525356A (ja) 変異ａａｖ、及び、細胞、臓器並びに組織への遺伝子導入のための組成物、方法並びに使用法
US20230242941A1 (en) Methods and compositions for administering recombinant viral vectors
CN115960921B (zh) 一组肝靶向新型腺相关病毒的获得及其应用
Kochergin-Nikitsky et al. Tissue and cell-type-specific transduction using rAAV vectors in lung diseases
JP2025527658A (ja) 組換えアデノ随伴ウイルス及びその使用
US20240115738A1 (en) Methods and compositions for treatment of cystic fibrosis
EA050636B1 (ru) Композиции и способы лечения муковисцидоза
US11345927B2 (en) Compositions for reducing sarcolipin expression and preventing and treating muscular dystrophy and cardiomyopathy and methods of use
WO2025259575A9 (en) Methods and compositions for treatment of duchenne muscular dystrophy
WO2025039622A1 (zh) 经修饰的腺相关病毒载体及其在治疗中枢神经系统疾病中的用途
AU2024305531A1 (en) Materials and methods for the treatment of neurofibromin 1 mutations and diseases resulting therefrom
HK1217916B (zh) 嵌合腺相關病毒/博卡病毒細小病毒載體

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20220412